01—Abstract
Summary
Summary of the 8-K filed July 3, 2024. Cited figures are marked; the original filing is the authoritative source.
On July 2, 2024, Quest Diagnostics (DGX) signed an Equity Purchase Agreement, through its subsidiary Ontario Inc., to acquire LifeLabs Inc. and BPC Lab Finance LP from Borealis Infrastructure, BPC Health Trust, and the OMERS pension plan.
The cash purchase price is approximately CAN$1.35 billiona (about US$985 million), including net debt and subject to customary adjustments. Quest guarantees the buyer's obligations. LifeLabs is Canada's leading community laboratory and digital health connectivity provider, with about 6,500 employees, and the company expects the deal to generate roughly CAN$970 million (about US$710 million) in annual revenue.
For investors, the key economics are that Quest expects the deal to be slightly dilutive to GAAP EPS, mainly from intangible amortization, but accretive to adjusted EPS within the first 12 months after closing. Quest plans to fund it with cash on hand and debt, which implies higher leverage and interest costs. The deal meets Quest's criteria on growth, profitability, and returns, and management expects to close by year-end 2024.
Quest also already has an existing relationship with LifeLabs through the Global Diagnostic Network and a reference-testing arrangement. Closing is subject to consents from certain key LifeLabs customers, Competition Act (Canada) clearance, and no prohibitive order under the Investment Canada Act.
A termination fee is payable by the buyer if the agreement is terminated for failure to obtain these approvals, unless that failure was primarily caused by a Seller or Target Entity breach. The filing does not include a full quantitative reconciliation of projected adjusted EPS, and the full agreement will be filed with the Q2 2024 Form 10-Q.
02—Key points
Key Highlights
- Quest Diagnostics agreed to acquire LifeLabs, Canada's leading community laboratory and digital health connectivity provider, for approximately CAN$1.35 billion (about US$985 million), including net debt.
- The acquisition is expected to generate about CAN$970 million (about US$710 million) in annual revenue.
- Quest expects the deal to be slightly dilutive to GAAP EPS, primarily from intangible amortization, but accretive to adjusted EPS within 12 months of closing.
- Funding will come from cash on hand and debt, which raises leverage and interest expense.
- Closing is expected by the end of 2024 and depends on key customer consents, Canadian Competition Act clearance, and no prohibitive Investment Canada Act order.
- A termination fee is payable by the buyer if the deal fails on regulatory or consent grounds, unless the failure was primarily caused by seller or target breach.
- The full Equity Purchase Agreement will be filed as an exhibit to the Q2 2024 Form 10-Q.
03—Questions
Frequently Asked Questions
Why is Quest acquiring LifeLabs?
Quest says LifeLabs fits its strategy of expanding access to advanced diagnostics in Canada. Quest plans to add its specialized testing expertise, innovation, and resources, including online scheduling, faster patient service processing, and data security enhancements, while LifeLabs keeps its brand, headquarters, and management. The company also cites an existing relationship through the Global Diagnostic Network and a test-reference arrangement.
How will the acquisition affect Quest's earnings?
Quest expects the deal to be slightly dilutive to GAAP EPS, mainly because of amortization of acquired intangibles and other items. It expects the deal to be accretive to adjusted EPS in the first 12 months after closing. Quest has not provided a full reconciliation of projected adjusted EPS to projected diluted EPS, citing uncertainty in purchase accounting and transaction costs.
What could prevent the deal from closing?
Closing depends on consents from certain key LifeLabs customers, clearance under the Canadian Competition Act, and no notice or order under the Investment Canada Act that prohibits closing. The buyer owes a termination fee if the deal is terminated because these approvals are not obtained within the agreed timeframe, unless the failure was primarily due to a breach by the sellers or target entities.
How will Quest pay for LifeLabs?
Quest expects to fund the acquisition with cash on hand and new debt. The filing does not disclose the specific financing mix or amounts, so investors should watch for updates on borrowing plans and resulting leverage in future filings.
When is the deal expected to close, and where can investors read the full terms?
Quest expects the transaction to close by the end of 2024, subject to closing conditions and approvals. The summary in the 8-K is not complete. The full Equity Purchase Agreement will be filed as an exhibit to Quest's Form 10-Q for the quarter ended June 30, 2024, which investors should review for representations, warranties, and covenants.
04—Continue